Bookmark
Forward
Explore Literature Results
Explore Clinical Trials Results
QuickView for programmed cell death 1 ligand 1 protein, human (compound)
Most Relevant Literature
- Modeling tumour heterogeneity of PD-L1 expression in tumour progression and adaptive therapy.
- The regulation of N6-methyladenosine modification in PD-L1-induced anti-tumor immunity.
- Lentinan-laden microspheres reprogram the tumor microenvironment and improve anti-PD-L1 efficacy.
- Targeting ZDHHC9 potentiates anti-programmed death-ligand 1 immunotherapy of pancreatic cancer by mo…
- Machine learning predicts cancer subtypes and progression from blood immune signatures.
Most Relevant Clinical Trials
- The Role of Programmed Death Ligand -1 (Pdl-1) in Lung Cancer
- Safety Study of Anti-Programmed Death-Ligand 1 in Hematologic Malignancy
- REirradiation and Programmed Cell Death Protein 1 (PD-1) Blockade On Recurrent Squamous Cell Head an…
- Coformulation of Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab (MK-3475) Monotherapy fo…
- First In Human Study With ABBV-CLS-579 When Given Alone Or In Combination With Programmed Cell Death…
